Remarkably, our study shows that inhibition or downregulation of PDGFR-α and PDGFR-β by miR-34a/c antagonizes tumorigenicity and increases sensitivity to TRAIL-induced cell death with important therapeutic application for future anti-tumor therapy of lung cancer. This evidence concerns the gene PDGFRA and lung carcinoma.